TITLE:
Neurogen Brain Balancing: A Novel Passive, Non-Invasive Neurobiomodulation Modality for Brain Health
AUTHORS:
Stefan J. Kasian, Rachel Turetzky
KEYWORDS:
Chronic Pain, EEG, Low-Intensity Pulse Transcranial Electrical Signaling, Mental Health, Neurobiomodulation, PTSD, Traumatic Brain Injury, Veterans
JOURNAL NAME:
Health,
Vol.17 No.4,
April
17,
2025
ABSTRACT: Neurogen Brain Balancing (NGBB) is an innovative, non-invasive neurobiomodulation technology designed to optimize brainwave function and restore neurological balance. Unlike conventional neurofeedback, which requires active client participation, NGBB delivers therapeutic benefits passively through low-intensity pulse transcranial electrical signaling (LIP-tES) and EEG-guided protocols. This modality has demonstrated promising clinical outcomes in managing post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), anxiety, depression, attention-deficit/hyperactivity disorder (ADHD), insomnia, chronic pain, and neurodegenerative conditions. An observational study of 80 veterans who completed four weekly NGBB sessions found that 80% reported improvements in their conditions. The most commonly ameliorated symptoms included PTSD, anxiety, depression, sleep disturbances, chronic pain, cognitive dysfunction, and brain fog. NGBB’s passive nature makes it particularly suitable for individuals who may struggle with modalities requiring active participation, such as psychotherapy and traditional neurofeedback, due to cognitive overload, trauma, or attentional impairments. Additionally, its minimal side effect profile positions it as a compelling alternative to pharmaceuticals and other invasive interventions. This paper provides an in-depth exploration of neurobiomodulation, reviews clinical case studies, and examines emerging data supporting NGBB’s efficacy. By leveraging the brain’s inherent neuroplasticity, NGBB offers a scalable, non-invasive solution for neurological rehabilitation, with potential applications across diverse clinical populations. Continued research, including randomized controlled trials and biomarker-driven validation, will further elucidate its therapeutic potential and optimize treatment protocols.